Compare DY & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | ARWR |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.2B |
| IPO Year | 1995 | 2009 |
| Metric | DY | ARWR |
|---|---|---|
| Price | $483.26 | $79.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $425.30 | $83.40 |
| AVG Volume (30 Days) | 602.0K | ★ 1.5M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.71 | ★ 99.80 |
| EPS | ★ 3.00 | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $30.96 | N/A |
| Revenue Next Year | $9.49 | N/A |
| P/E Ratio | $154.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $233.00 | $14.30 |
| 52 Week High | $566.47 | $84.55 |
| Indicator | DY | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 57.26 |
| Support Level | $335.20 | $70.05 |
| Resistance Level | $490.00 | $82.26 |
| Average True Range (ATR) | 22.75 | 3.83 |
| MACD | -1.78 | 0.55 |
| Stochastic Oscillator | 82.61 | 68.16 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.